America’s Youth Suicide Crisis: How An Unprecedented Epidemic Spiraled Out of Control

by Vignesh Subramanian, May 15, 2024

In 2023, the Centers for Disease Control and Prevention (CDC) published up-to-date data on suicide rates among American youth that stunned public health and medical professionals nationwide. The federal report, issued in June, found that the overall suicide rate among U.S. youth ages 10 to 24 had surged 62% over the prior two decades (2001-2021), after decades of prior decline (Curtin & Garnett, 2023). On average, 11 young Americans died by suicide out of every 100,000 each year during this period; for children ages 10-14, the suicide rate had tripled from 2007-2018 (from 0.9 to 2.9 people per 100,000); for adolescents ages 15-19, it rose 57% from 2009-2017 (from 7.5 to 11.8 people per 100,000); and for young adults ages 20-24, it rose 63% over the entire period (from 11.9 people in 2001 to 19.4 in 2021 per 100,000). The findings painted a stark picture of a nation in the throes of a full-fledged crisis, with millions of its young people suffering in silence and thousands compelled by circumstance to take their own lives. 

Yet this grim milestone was seen by many as preceded by years of warning signs. Well before the COVID-19 pandemic, CDC reports noted that suicide rates among U.S. youth ages 10-24 had jumped 57.4% from 2007-2018 (rising from less than 7 deaths per 100,000 to nearly 11), with even such states as New York, New Jersey, and Massachusetts – widely viewed as having strong safety nets for at-risk youth – seeing increases in youth suicide rates ranging from 40% to 60% over that single decade (Curtin, 2020). The issue notably remained pervasive for young Americans of all ages. Between 2007 and 2019, the suicide rate among pre-teens ages 8 to 12 surged a disturbing 166% (Penfold, 2021), with 8.4% of children as young as nine and ten years old reporting suicidal thoughts and 1.3% even making attempts (Janiri et al., 2020). From 2018-2019, 18.8% of adolescents ages 12-17 seriously considered attempting suicide, with 15.7% making a suicide plan, 8.9% attempting suicide at least once, and 2.5% making an attempt that required medical treatment (Ivey-Stephenson et al., 2020), corresponding to around 1.24 million medically attended suicide attempts by American teenagers nationwide. This data came on the heels of separate studies finding that suicide rates more than doubled in the preceding decade (from approximately 2 deaths per 100,000 people in 2008 to 5 per 100,000 in 2018) for adolescents as young as thirteen and fourteen years old (Levine et al., 2023). And since 2019, emerging American adults ages 18-25 have demonstrated the highest prevalence of both serious suicidal thoughts (11.8% in 2019, rising to 13.6% by 2022) and suicide attempts made (1.8% in 2019, rising to 2.7% by 2021 before dropping to 2.1% by 2022) among adults across all age groups (National Institute of Mental Health, 2024; Richesson et al., 2022; Keating & Rudd-Arieta, 2021).

In 2023, the Centers for Disease Control and Prevention (CDC) published up-to-date data on suicide rates among American youth that stunned public health and medical professionals nationwide. The federal report, issued in June, found that the overall suicide rate among U.S. youth ages 10 to 24 had surged 62% over the prior two decades (2001-2021), after decades of prior decline (Curtin & Garnett, 2023). On average, 11 young Americans died by suicide out of every 100,000 each year during this period; for children ages 10-14, the suicide rate had tripled from 2007-2018 (from 0.9 to 2.9 people per 100,000); for adolescents ages 15-19, it rose 57% from 2009-2017 (from 7.5 to 11.8 people per 100,000); and for young adults ages 20-24, it rose 63% over the entire period (from 11.9 people in 2001 to 19.4 in 2021 per 100,000). The findings painted a stark picture of a nation in the throes of a full-fledged crisis, with millions of its young people suffering in silence and thousands compelled by circumstance to take their own lives. 

Yet this grim milestone was seen by many as preceded by years of warning signs. Well before the COVID-19 pandemic, CDC reports noted that suicide rates among U.S. youth ages 10-24 had jumped 57.4% from 2007-2018 (rising from less than 7 deaths per 100,000 to nearly 11), with even such states as New York, New Jersey, and Massachusetts – widely viewed as having strong safety nets for at-risk youth – seeing increases in youth suicide rates ranging from 40% to 60% over that single decade (Curtin, 2020). The issue notably remained pervasive for young Americans of all ages. Between 2007 and 2019, the suicide rate among pre-teens ages 8 to 12 surged a disturbing 166% (Penfold, 2021), with 8.4% of children as young as nine and ten years old reporting suicidal thoughts and 1.3% even making attempts (Janiri et al., 2020). From 2018-2019, 18.8% of adolescents ages 12-17 seriously considered attempting suicide, with 15.7% making a suicide plan, 8.9% attempting suicide at least once, and 2.5% making an attempt that required medical treatment (Ivey-Stephenson et al., 2020), corresponding to around 1.24 million medically attended suicide attempts by American teenagers nationwide. This data came on the heels of separate studies finding that suicide rates more than doubled in the preceding decade (from approximately 2 deaths per 100,000 people in 2008 to 5 per 100,000 in 2018) for adolescents as young as thirteen and fourteen years old (Levine et al., 2023). And since 2019, emerging American adults ages 18-25 have demonstrated the highest prevalence of both serious suicidal thoughts (11.8% in 2019, rising to 13.6% by 2022) and suicide attempts made (1.8% in 2019, rising to 2.7% by 2021 before dropping to 2.1% by 2022) among adults across all age groups (National Institute of Mental Health, 2024; Richesson et al., 2022; Keating & Rudd-Arieta, 2021).

Surges in suicidal ideation and attempts among young Americans subsequently contributed to sharp increases in long-running trends of associated emergency department (ED) visits and hospitalizations. From 2011-2020, pediatric ED visits by children, adolescents, and young adults ages 6-24 nearly doubled nationwide (from 4.8 million visits, or 7.7% of all pediatric ED visits, to 7.5 million, or 13.1% of all visits), even as the overall number of pediatric ED visits for all causes decreased (Bommersbach et al., 2023). This spike in visits included a five-fold increase in the number of pediatric ED visits for suicide-related symptoms (from 0.9% of all visits in 2011 to 4.2% in 2020), which now make up an average of 5% of all visits by this age group. This alarming trend has been substantiated by other large national studies examining related healthcare data. Analyses of insurance claims for 24.5 million youths ages 1-21 found that mental health-related inpatient hospital admissions surged 61% among this population between 2016-2021, alongside a 45% increase in mental health-related ED visits and a 74% increase in ED visits for suicidal ideation, attempts, and self-harm by 2022, with the increases being most pronounced for adolescents and young adults (Clarify Health Institute, 2022; Clarify Health Institute, 2023). A review of 4.8 million pediatric hospitalizations from 2009-2019 at U.S. acute care hospitals revealed that a diagnosis of suicide or self-injury made up 64% of all mental health-related hospitalizations (Arakelyan et al., 2023). Other studies have found that all mental-related pediatric ED visits among youths ages 3-17 rose 8% annually from October 2015 to February 2020 (compared to an average increase of just 1.5% for visits for other reasons) (Cushing et al., 2022), with 13% of all patients revisiting within 6 months, and that from 2019-2020 – the last full year before the pandemic – the overall number of behavioral health cases for youth under 18 increased 30%, with pediatric ED cases of suicide attempts and self-injury in particular having jumped 50% (Children’s Hospital Association, 2023). 

It was this already escalating crisis that proceeded to become severely exacerbated by the pandemic: in 2021, the first full year of the pandemic in the United States, the national suicide rate among youths 10-24 years old returned to 2018 highs after two years of moderate declines (Stone et al, 2023; Curtin et al., 2022). The stressful impacts of the period were acutely felt by young Americans of varied educational levels. The CDC found that 22% of U.S. high school students – including roughly a third (30%) of female students (Gaylor et al., 2023) – had seriously considered suicide the previous year, with 18% making a plan and 10% attempting at least once (drastically up from 16%, 13%, and 8% a decade prior, respectively) (CDC, 2023b). Separate reports also noted that three months into the pandemic, roughly a quarter (25.5%) of young people ages 18-24 – the largest age demographic on college campuses – had seriously considered suicide in the prior 30 days (Czeisler et al., 2020), and a Healthy Minds Survey found that 15% of U.S. college students surveyed during the 2021-2022 school year had seriously considered suicide, the highest rate in the survey’s 15-year history (Eisenberg et al., 2023). The CDC further found that beginning in April 2020 – shortly after the start of the pandemic in the United States – and proceeding through October of that same year, the proportion of mental health emergency-related visits among all pediatric ED visits surged 24% for children ages 5 to 11 and 31% for those ages 12 to 17 relative to 2019 levels (Leeb et al., 2020). In the second full year of the pandemic (from March 2021 to February 2022), pediatric mental health-related ED visits for youths ages 5-17 collectively jumped another 7%; the percentage of their ED visits resulting in psychiatric inpatient admission rose 8%; and the mean length of their stay increased 4%, with youth in both years of the pandemic more likely to spend two or more nights experiencing prolonged boarding (Overhage et al., 2023). 

Overall, amid the pandemic, U.S. youth and young adults ages 10-24 began to represent 15% of all suicides nationally, and demonstrated exorbitantly high rates of ED visits for mental health emergencies and self-harm in particular, with 354.4 such visits per 100,000 members of this population in 2020 (compared to 128.9 visits per 100,000 people for middle-aged adults) (CDC, 2023a). Adolescent girls were noted to be at particularly high risk, with the proportion of ED visits for suicide attempts among those ages 12-17 jumping 50.6% from February-March 2019 to February-March 2021 (compared to just a 3.7% increase for boys and young men of the same ages) (Yard et al., 2021). Girls and young women ages 10-24 overall demonstrated a 43.6% increase in visits for suicidal ideation over the past two decades (Overhage et al., 2023), as well as an associated ED visit rate in 2021 measuring roughly double that of boys and young men (though the latter themselves consistently report some of the largest increases in suicide rates, including an 8% increase among those ages 15-24 in the same year) (CDC, 2023a; Curtin et al., 2022). Even more stark disparities in suicide rates have been discovered among other marginalized groups – with over a quarter of LGBTQ+ youths reporting attempting suicide in 2021, a significantly higher rate than that of their peers (Jones et al., 2022); higher percentages of American Indian and Alaska Native (AI/AN) youths experiencing suicidality than any other race or ethnicity that same year; Latina adolescents consistently being twice as likely to attempt suicide than their peers of the same race (Ivey-Stephenson et al., 2020); Black youths experiencing the largest percentage increases in suicides among any racial group in recent years (Stone et al., 2023); and Asian American/Pacific Islander (AAPI) adolescents and young adults being the only racial group to have suicide rank as their leading cause of death (CDC, 2018) – that merit an entirely separate article beyond the limitations of this paper.

For several years, U.S. lawmakers have demonstrated a propensity to pin the blame for the country’s youth suicide crisis entirely on the pandemic – despite such claims not covering the full story (Warner & Zhang, 2022). It is clear that this crisis had already reached epidemic proportions by the time COVID-19 took hold in early 2020. Yet even if this myopic view of its origins is genuinely held by those in elected office, it has failed to translate into substantive policy reforms that might address the widespread and life-threatening struggles with mental health currently faced by millions of young Americans. Nearly two full years into the pandemic (in October 2021), the American Academy of Pediatrics (AAP), the American Academy of Child and Adolescent Psychiatry, and the Children’s Hospital Association joined together to issue the unprecedented declaration of a national state of emergency in children’s mental health (AAP et al., 2021). The declaration took into account “dramatic increases” in rates of pediatric suicidality and ED visits for mental health emergencies, and called upon “policymakers at all levels of government and advocates for children and adolescents to join us” in working to institute a series of reforms, including securing sustainable funding for mental health screenings, establishing suicide prevention programs and risk assessments in schools and primary care, and addressing acute care needs in hospital settings by expanding access to adequate numbers of beds, step-down programs from inpatient units, and short-stay stabilization units, among other measures (Hua et al., 2024). Less than two months later, the U.S. Surgeon General echoed these calls, issuing an advisory highlighting the scope of the youth mental health crisis and outlining recommendations for governments and private healthcare organizations to collaborate to support children’s emotional and social well-being (Office of the U.S. Surgeon General, 2021), and roughly a year later, the AAP and over 130 other healthcare organizations explicitly called upon the Biden administration to declare a federal national emergency in children’s mental health (AAP et al., 2022). Yet despite these high-profile calls to action, no comprehensive federal legislation has been passed to support crisis identification, prevention, and intervention services for youth in either community or hospital settings (Roubein & Beard, 2022), and President Biden has yet to declare a national emergency in youth mental health, neglecting an opportunity to mobilize the full leverage and resources of the federal government to address the crisis.

At the state and local levels, attempts to contend with the youth suicide crisis have hardly fared better. As of June 2023, while half of all U.S. states and D.C. have enacted laws over the past decade that uniformly require their K-12 schools and school districts to adopt suicide prevention and intervention policies and guidelines outlining how staff should respond to students exhibiting suicidal ideation, 25 states have still not done so, according to the American Foundation for Suicide Prevention (AFSP, 2023). Furthermore, while 13 states uniformly require K-12 school personnel to be annually trained in such prevention and intervention protocols, a plurality of states (24, plus D.C.) do not mandate such training to occur every year – raising the risk that recall of key protocols may be poor in an emergency – and another 13 states do not require training at all. 22 states also uniformly require schools to develop curricula for student education in either suicide awareness and prevention and/or mental health more generally, but a majority (28, plus D.C.) continue not to do so. Statewide policy is even less consistent at the collegiate level, with 22 states having enacted laws uniformly requiring colleges and universities to adopt various specified suicide prevention policies – ranging from printing hotline numbers on student ID cards and publicizing student mental health resource information to adopting institutional awareness programs or prevention and intervention strategies – while the majority of states (28, plus D.C.) lacked any laws establishing a uniform standard of preparedness for higher education institutions as of December 2022 (AFSP, 2022). The resulting patchwork of policies, fragmented across thousands of campuses and communities, fails to offer a comprehensive response to the nationwide youth suicide crisis that transcends their outskirts and borders. Meanwhile, conflicting guidelines on the ages at which youths are recommended to be screened early in childhood for suicide risk (the AAP recommends those ages 12 and up be universally screened annually, with those ages 8-11 screened when clinically indicated, while the U.S. Preventive Services Task Force argues there is insufficient evidence to justify screening any asymptomatic youths for suicide risk) continue to confuse localities and providers seeking to address the root causes of such ideation (Jenco, 2022). Hospitals and inpatient facilities are also becoming overwhelmed by surging numbers of suicidal young adults, adolescents, and increasingly younger-aged children who arrive in EDs already at their crisis point (Richtel & Flanagan, 2022), with no end to this epidemic in sight as of yet.

Today, suicide is the third leading cause of death among young Americans ages 15-24 and the second leading cause of death among those ages 10-14. The United States loses far more of its young people to suicide than any other developed nation each year, with the total number of lives lost representing a disproportionately large segment of its youth population (Doran & Kinchin, 2020). For every young person lost to suicide, roughly 1,000 others are estimated to be considering and struggling with the idea of attempting (National Alliance on Mental Illness, 2024) – but every one of these suicides is preventable. Despite having an abundance of options with which to act, the nation’s leaders have collectively and inexcusably allowed this crisis to spiral out of control, and in so doing, have left millions of vulnerable children, adolescents, and young adults at risk. We must act swiftly and decisively to change course, advancing reforms that will reshape national policy to confront these harsh clinical realities – and ultimately save lives. 

  1. American Academy of Pediatrics, American Academy of Child and Adolescent Psychiatry, & Children’s Hospital Association. (2021). AAP-AACAP-CHA declaration of a national emergency in child and adolescent mental health. American Academy of Pediatrics. https://www.aap.org/en/advocacy/child-and-adolescent-healthy-mental-development/aap-aacap-cha-declaration-of-a-national-emergency-in-child-and-adolescent-mental-health/ 
  2. American Academy of Pediatrics, American Academy of Child and Adolescent Psychiatry, & Children’s Hospital Association. (2022). Health organizations urge the Biden administration to declare a federal national emergency in children’s mental health. American Academy of Pediatrics. https://www.aap.org/en/news-room/news-releases/aap/2022/health-organizations-urge-the-biden-administration-to-declare-a-federal-national-emergency-in-childrens-mental-health/ 
  3. American Foundation for Suicide Prevention. (2023). Policy priority: Suicide prevention in schools (K-12). American Foundation for Suicide Prevention Public Policy Office. https://www.datocms-assets.com/12810/1686164392-afsp-k-12-schools-issue-brief.pdf
  4. American Foundation for Suicide Prevention. (2022). Policy priority: Suicide prevention on university and college campuses. American Foundation for Suicide Prevention Public Policy Office. https://www.datocms-assets.com/12810/1677181582-afsp-colleges-universities-issue-brief.pdf 
  5. Arakelyan, M., Freyleue, S., Avula, D., McLaren, J. L., O’Malley, A. J., & Leyenaar, J. K. (2023). Pediatric mental health hospitalizations at acute care hospitals in the US, 2009-2019. JAMA, 329(12), 1000-1011. DOI: 10.1001/jama.2023.1992 
  6. Bommersbach, T. J., McKean, A. J., Olfson, M., & Rhee, T. G. (2023). National trends in mental health–related emergency department visits among youth, 2011-2020. JAMA, 329(17), 1469-1477. DOI: 10.1001/jama.2023.4809
  7. Centers for Disease Control and Prevention. (2018). LCWK1 – Deaths, percent of total deaths, and death rates for the 15 leading causes of death in 5-year age groups, by race and Hispanic origin, and sex: United States, 2017. Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System, 1-195. https://www.cdc.gov/nchs/data/dvs/lcwk/lcwk1_hr_2017-a.pdf 
  8. Centers for Disease Control and Prevention. (2023a). Disparities in Suicide. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. https://www.cdc.gov/suicide/facts/disparities-in-suicide.html 
  9. Centers for Disease Control and Prevention. (2023b). Youth Risk Behavior Survey data summary & trends report: 2011-2021. Centers for Disease Control and Prevention, Division of Adolescent and School Health. https://www.cdc.gov/healthyyouth/data/yrbs/pdf/YRBS_Data-Summary-Trends_Report2023_508.pdf 
  10. Children’s Hospital Association. (2023). The latest pediatric mental health data. Children’s Hospital Association. https://www.childrenshospitals.org/news/childrens-hospitals-today/2023/04/the-latest-pediatric-mental-health-data 
  11. Clarify Health Institute. (2022). The kids are not alright – Pediatric mental health care utilization from 2016-2021. Clarify Health. clarifyhealth.com/wp-content/uploads/2022/09/The-Clarify-Health-Institute-Research-Brief_The-Kids-Are-Not-Alright.pdf 
  12. Clarify Health Institute. (2023). The kids are not alright – Mental health utilization among children and young adults: 2016-2022. Clarify Health. clarifyhealth.com/wp-content/uploads/2023/05/Clarify-Health-Institute-Research-Brief-The-Kids-Are-Not-Alright-2023.pdf 
  13. Curtin, S.C. (2020). State suicide rates among adolescents and young adults aged 10–24: United States, 2000–2018. Centers for Disease Control and Prevention, National Vital Statistics Reports, 69(11), 1-10. https://www.cdc.gov/nchs/data/nvsr/nvsr69/nvsr-69-11-508.pdf
  14. Curtin, S .C. & Garnett, M. F. (2023). Suicide and homicide death rates among youth and young adults aged 10–24: United States, 2001–2021. Centers for Disease Control and Prevention, National Center for Health Statistics (471). DOI: 10.15620/cdc:128423
  15. Curtin, S. C., Garnett, M. F., & Ahmad, F. B. (2022). Provisional Numbers and Rates of Suicide by Month and Demographic Characteristics: United States, 2021. Centers for Disease Control and Prevention, National Vital Statistics Reports, (24), 1-7. https://www.cdc.gov/nchs/data/vsrr/vsrr024.pdf 
  16. Cushing, A. M., Liberman, D. B., Pham, P. K., Michelson, K. A., Festekjian, A., Chang, T. P., & Chaudhari, P. P. (2022). Mental health revisits at US pediatric emergency departments. JAMA Pediatrics, 177(2), 168-176. DOI: 10.1001/jamapediatrics.2022.4885
  17. Czeisler, M. E., Lane, R. I., Petrosky, E., Wiley, J. F., Christensen, A., Njai, R., Weaver, M. D., Robbins, R., Facer-Childs, E. R., Barger, L. K., Czeisler, C. A., Howard, M. E., & Rajaratnam, S. M. W. (2020). Mental health, substance use, and suicidal ideation during the COVID-19 pandemic — United States, June 24–30, 2020. Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, 69(32), 1049-1057. DOI: 10.15585/mmwr.mm6932a1 
  18. Doran, C. M. & Kinchin, I. (2020). Economic and epidemiological impact of youth suicide in countries with the highest human development index. PLOS One, 15(5). DOI: 10.1371/journal.pone.0232940
  19. Eisenberg, D., Lipson, S. K., Heinze, J., Zhou, S., Vyletel, B., Henry, H., Fucinari, J., Murphy, M., Voichoski, E., & Inscore, A. (2023). The Healthy Minds Study: 2021-2022 data report. Healthy Minds Network. https://healthymindsnetwork.org/wp-content/uploads/2023/08/HMS-National-Report-2021-22_full.pdf
  20. Gaylor, E. M., Krause, K. H., Welder, L. E., Cooper, A. C., Ashley, C., Mack, K. A., Crosby, A. E., Trinh, E., Ivey-Stephenson, A. Z., & Whittle, L. (2023). Suicidal thoughts and behaviors among high school students — Youth Risk Behavior Survey, United States, 2021. Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, 72(1), 45-54. DOI: 10.15585/mmwr.su7201a6
  21. Hua, L. L., Lee, J., Rahmandar, M. H., Sigel, E. J., Committee on Adolescence, & Council on Injury, Violence, and Poison Prevention. (2024). Suicide and suicide risk in adolescents. Pediatrics, 153(1). DOI: 10.1542/peds.2023-064800
  22. Ivey-Stephenson, A. Z., Demissie, Z., Crosby, A. E., Stone, D. M., Gaylor, E., Wilkins, N., Lowry, R., & Brown, M. (2020). Suicidal ideation and behaviors among high school students — Youth Risk Behavior Survey, United States, 2019. Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, 69(1), 47-55. DOI: 10.15585/mmwr.su6901a6 
  23. Janiri, D., Doucet, G., Pompili, M., Sani, G., Luna, B., Brent, D., & Frangou, S. (2020). Risk and protective factors for childhood suicidality: a US population-based study. The Lancet Psychiatry, 7(4), 317-326. DOI: 10.1016/S2215-0366(20)30049-3
  24. Jenco, M. (2022). AAP urges suicide screening despite USPSTF call for more research. American Academy of Pediatrics News. https://publications.aap.org/aapnews/news/19948/AAP-urges-suicide-screening-despite-USPSTF-call 
  25. Jones, S. E., Ethier, K. A., Hertz, M., DeGue, S., Le, V. D., Thornton, J., Lim, C., Dittus, P. J., & Geda, S. (2022). Mental health, suicidality, and connectedness among high school students during the COVID-19 pandemic — Adolescent behaviors and experiences survey, United States, January–June 2021.  Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, 71(3), 16-21. https://www.cdc.gov/mmwr/volumes/71/su/pdfs/su7103a1-a5-H.pdf 
  26. Keating, S. R. & Rudd-Arieta, M. (2021). Emerging adults’ attitudes and beliefs about suicide and technology/social media. The Journal for Nurse Practitioners, 17(7), 833-839. DOI: 10.1016/j.nurpra.2021.04.010 
  27. Leeb, R. T., Bitsko, R. H., Radhakrishnan, L., Martinez, P., Njai, R., & Holland, K. M. (2020). Mental health–related emergency department visits among children aged <18 years during the COVID-19 pandemic — United States, January 1–October 17, 2020. Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, 69(45), 1675-1680. DOI: 10.15585/mmwr.mm6945a3
  28. Levine, R. S., Levine, E. M., Rubenstein, A., Muppala, V., Mejia, M. C., Gonzalez, S., Zoorob, R. J., Hennekens, C. H., & Wood, S. K. (2023). Continuing alarming increases in suicide in American youths: Clinical and research challenges. Annals of Pediatrics and Child Health. https://www.jscimedcentral.com/jounal-article-pdfd/Annals-of-Pediatrics-and-Child-Health/pediatrics-11-1301.pdf 
  29. National Institute of Mental Health. (2024). Suicide. The National Institutes of Health. https://www.nimh.nih.gov/health/statistics/suicide 
  30. National Alliance on Mental Illness (2024). What you need to know about youth suicide. NAMI. https://www.nami.org/Your-Journey/Kids-Teens-and-Young-Adults/What-You-Need-to-Know-About-Youth-Suicide 
  31. Office of the U.S. Surgeon General. (2021). Protecting youth mental health: The U.S. Surgeon General’s advisory. U.S. Department of Health and Human Services, Office of the U.S. Surgeon General. https://www.hhs.gov/surgeongeneral/priorities/youth-mental-health/index.html
  32. Overhage, L., Hailu, R., Busch, A. B., Mehrotra, A., Michelson, K. A., & Huskamp, H. A. (2023). Trends in acute care use for mental health conditions among youth during the COVID-19 pandemic. JAMA Psychiatry, 80(9), 924-932. DOI: 10.1001/jamapsychiatry.2023.2195
  33. Penfold, R. (2021). Addressing the crisis of youth suicide in America. Kaiser Permanente Washington Health Research Institute. https://www.kpwashingtonresearch.org/news-and-events/blog/2021/addressing-crisis-youth-suicide-america 
  34. Richesson, D., Magas, I., Brown, S., Hoenig, J. M., Cooper, P. M., Gyawali, S., Smith, T., & Yen, J. (2022). Key Substance Use and Mental Health Indicators in the United States: Results from the 2021 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/sites/default/files/reports/rpt39443/2021NSDUHFFRRev010323.pdf 
  35. Richtel, M. & Flanagan, A. (2022). Hundreds of suicidal teens sleep in emergency rooms. Every night. The New York Times. https://www.nytimes.com/2022/05/08/health/emergency-rooms-teen-mental-health.html 
  36. Roubein, R. & Beard, M. (2022). Congress is working on legislation to address children’s mental health crisis. The Washington Post. www.washingtonpost.com/politics/2022/06/01/congress-is-working-legislation-address-children-mental-health-crisis/ 
  37. Stone, D. M., Mack, K. A., & Qualters, J. (2023). Notes from the field: Recent changes in suicide rates, by race and ethnicity and age group — United States, 2021. Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, 72(6), 160-162. DOI: 10.15585/mmwr.mm7206a4 
  38. Warner, J. & Zhang, J. (2022). ‘We have essentially turned a blind eye to our own children for decades’: Why we need to stop politicizing children’s mental health. The Washington Post Magazine. https://www.washingtonpost.com/magazine/2022/03/21/childrens-mental-health-crisis-politicization/ 
  39. Yard, E., Radhakrishnan, L., Ballesteros, M. F., Sheppard, M., Gates, A., Stein, Z., Hartnett, K., Kite-Powell, A., Rodgers, L., Adjemian, J., Ehlman, D. C., Holland, K., Idaikkadar, N., Ivey-Stephenson, A., Martinez, P., Law, R., & Stone, D. M. (2021). Emergency department visits for suspected suicide attempts among persons aged 12–25 years before and during the COVID-19 pandemic — United States, January 2019–May 2021. Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, 70(24), 888-894. DOI: 10.15585/mmwr.mm7024e1 

The Possible Anti-depressant Effects of Magic Mushrooms

By Maisha Pathan, March 9, 2024

Depression is a debilitating condition that affects up to 17.8% of American adults as of
2023 (Witters). Although there are countless treatment options in the form of antidepressants,
and therapy, sometimes, these treatments may still not be enough to provide relief for those
suffering from depression. Shrooms, also known as magic mushrooms may be an emerging
answer to those seeking an alternative. This unorthodox form of treatment called
psilocybin-assisted therapy (PAT) is gaining popularity, and the results are significant enough to
be brought to the public’s attention. In PAT, the patient is given a dose of the psychedelic
psilocybin, also known as magic mushrooms, in a controlled setting while their assigned
therapist stands by to monitor the experience. Despite its low toxicity and even being safer than
nicotine and aspirin, the stigma surrounding psychedelics causes people to hesitate even
considering this as an option, on top of which it’s still a controlled substance by the government
(Lowe et al. 20). However, research obtained from clinical trials shows that in a controlled
environment and administered by a trusted professional psilocybin has a powerful impact on
depressive symptoms, and many participants report improvement in their condition after their
sessions. For the people struggling with treatment-resistant depression, severe depression, or
anyone who finds that medication and therapy aren’t helping them: psilocybin-assisted therapy
could be a viable option for treating depression and should be offered alongside therapy and
medication.


Historically, psilocybin mushrooms have been in use for centuries, prominently in the
Aztec empire around the 15th century. The substance was referred to as “god’s flesh” in Nahuatl
and used in religious and healing rituals (Nichols 679). However, it wasn’t until 1957, when
Albert Hoffman a chemist who (also created LSD) isolated psilocybin from a Mesoamerican
psilocybin mushroom, and published its effects, that magic mushrooms entered modern
American society (Nichols 680) . Although the substance was then used in psychedelic therapy,
it became popularized for its recreational use during the 60’s aided by the hippie movement,
until the USA passed the Comprehensive Drug Abuse Prevention and Control Act of 1970,
which marked it as an illicit drug along with LSD and other psychedelics. Despite these
restrictions, psilocybin continued to be used recreationally by citizens and has been gaining
more traction in media.


Major depressive disorder is a serious depressive disorder that can have a lasting impact
on the brain. This damage essentially rewires the brain which can keep the person in their
depressive state for a prolonged amount of time. The compounds that makeup psilocybin can
sometimes reverse, or rewire, the damage depression does to the brain. According to an article
published by Healthline, a medical information website, depression can shrink regions of the
brain governing memory (hippocampus), emotion (amygdala), and cognitive functions
(prefrontal cortices). As a result of shrinking, function in these brain regions such as emotional
regulation and interest, memory, and concentration are also diminished (“5 Ways Depression
Can Physically Affect the Brain”). Psilocybin, specifically psilocin comes into play here due to
its role as a subtype of serotonin receptor. It activates a serotonin receptor called the 5-HT2A
which increases serotonin levels similar to SSRIs (2-Minute Neuroscience: Psilocybin, 0:16). In
a study conducted by researchers at Weill Cornell Medicine, an fMRI was used to show how the
activation of the 5-HT2A serotonin receptor by psilocin affected the brain landscape. The results showed that on psilocin, the brain lowered energy barriers between different regional
connections in the brain which allowed regions of the brain that were typically not stimulated to
be activated. Due to the flattening of the brain’s energy landscape, new connections could be
made between different brain regions, enabling neuroplasticity and promoting neurogenesis,
which is generation of new neurons. This opens up space that allows the brain to rewire itself,
and if the psilocybin is taken in a clinical setting such as in a PAT session, old patterns of
thinking can be replaced with new, expansive thought patterns which can reverse the effects of
depression on the brain by fostering new connections (Kuceyeski).


The structure of PAT is what makes it so successful and extremely safe in treating
depression. It’s is controlled by doctors and therapists in a clinical setting and is spread
throughout three stages: a preparatory stage, an administration stage, and an integration stage
(Schuitmaker 2). Each stage of PAT plays a significant role in how effective the treatment will
be for the patient while maintaining the environment in a controlled setting.


In the preparatory stage, participants attend several psychotherapy sessions to set their
goals and intentions for their experience. This creates the set and setting. Although individuals’
experiences on psilocybin vary from person to person an important factor to the experience is set
and setting. An article analyzing PAT in medicine by Cureus, a peer-reviewed medical journal,
explains that set refers to a patient’s goals and intentions for their psilocybin experience and is
discussed with their therapist so that it could be used to guide the individual and keep them on
track. The setting refers to the patient’s mental, physical, and emotional state prior to and during
the treatment. Attending these preparatory therapy sessions helps the therapist assess when and
where treatment should take place (Ziff et al. 7).


Once the patient is prepared, the next stage is “administration” which the Yale Manual for
Psilocybin-Assisted Therapy of Depression details. Typically, on the day of administration, the
patient is taken to a homey, welcoming room, where they lie down on the couch, put on
headphones, run a musical playlist, and wear a blindfold. The dose of psilocybin provided can
vary but typically is less than 1 gram and based on what the participant can handle. The music,
lying down, and blindfold work together to create a relaxing environment where the patient can
feel safe. They know that if they need any support they have their therapist right there next to
them. These measures create a controlled environment for the patient, minimizing possible
adverse reactions like anxiety or paranoia which can lead to nausea or vomiting. Once the patient
is settled and has consumed their psilocybin dose, the drug slowly takes effect, guiding them on a
journey into the depths of their mind. The therapist only guides the patient when needed based on
the goals and intentions set in the preparatory sessions, and otherwise does not interfere with the
psilocybin trip (Guss et al. 45-50).


The day after administration takes us to the third stage, “integration.” Integration
consists of several sessions through the following weeks during which the therapist asks the
patient about their experience, what they saw, felt, learned, what they’d like to take away from
their experience, and how to integrate that into their lives (Guss et al. 51-60). Although all three
stages of psilocybin-assisted therapy are equally as important, integration ensures that the
positive experiences are incorporated into the patient’s life and have a lasting effect while the
negative experiences if any are worked through. This structuring makes the therapeutic
administration of psilocybin safe and maximizes the benefits the substance can provide a
patient.

The effectiveness of psilocybin-assisted therapy as a treatment is evident in a number of studies.
In an article published by Johns Hopkins Medicine, the efficiency of using psilocybin to treat
major depression is explored through two studies conducted under their Psychiatry and
Behavioral Sciences department. The results found from both studies showed that using
psychedelic therapy by giving each participant a dose of psilocybin followed by psychotherapy
significantly reduced the symptoms of depression in both studies. Half of the participants in the
first study entered remission from depression at the end of the four-week follow-up. In the
second study, participants with a long history of depression on antidepressants were provided two
doses of psilocybin in a few weeks. They took a GRID-Hamilton Depression Rating Scale before
and after. The results showed that 67% of the participants showed a reduction in their symptoms
after a week, and four weeks after treatment, 54% of participants in the study were in remission
(“Psychedelic Treatment with Psilocybin Relieves Major Depression, Study Shows”). In another
study conducted by the Psychiatric University Hospital of Zurich, 52 participants suffering from
major depressive disorder were treated with psilocybin-assisted therapy. Half of them were given
psilocybin while the other half, 26 individuals were given a placebo. The results showed that
psilocybin significantly decreased depressive symptoms in those who had it, more than those
who received a placebo along with their therapy sessions. By the end of the study 14 out of 26,
met the criteria for remission from depression on the Montgomery–Åsberg Depression Rating
scale. In comparison to the placebo group in which the treatment was technically seven required
therapy sessions, 4 out of 26 met the criteria for remission demonstrating that psilocybin was the
driving force for the symptom reductions (Rotz 7-10).


In one clinical PAT trial conducted by NYU School of Medicine, the participants were four
cancer patients struggling with depression and anxiety. At the end of their participation which
spanned 26 weeks, each patient demonstrated a significant reduction in their depressive
symptoms which resulted from the experiences they had during their trips.
Many people suffering from depression who participated in psilocybin-assisted therapy
clinical studies report having positive experiences that aided in reducing their depressive
symptoms. Chrissy, a 50-year-old female with stage 4 breast cancer stated “[The psilocybin
experience] brought my beliefs to life, made them real, something tangible and true – it made my
beliefs more than something to think about, really something to lean on and look forward to,”
(Malone et a. 4). Although Chrissy knew that she was still going to pass, she was able to accept
and even look forward to the time she had left. In a separate trial by the Faculty of Medicine at
Al-Hikma University, ten participants struggling with depression were treated their with
psilocybin-assisted therapy. During an integration session with their therapist, a young adult
known as Participant 1 stated, “My whole thought pattern changed. I was so relieved. My head
had never been clearer. I was so happy the day after cried to my trip buddy about how I could see
again…. I was on three different anti-depressants, valium, and sleeping pills. This stopped within
2 weeks of my first dose,” (Hisham et al. 3). Many other participants from the same study
reported the experience was mind-expanding, and gave them a more positive outlook in life. The
experiences of the participants in this particular study are consistent with the neuroplasticity
effect psilocybin can have on the brain which allows it to create new connections and eradicate
old, negative thought patterns.


Psilocybin-assisted therapy has proven to be a worthwhile treatment venture for many of the
patients who participated in treatment for their depressive disorders. It’s important to note that psilocybin in this case is being used for treatment, not for recreation or self-exploration and
because it is being used for treatment by entrusted clinics it poses a relatively low risk, if at all to
those who receive it. However, that is not to say that this should be an option for everyone.
Studies have shown that people who are genetically predisposed to psychotic disorders such as
Schizophrenia can be triggered if exposed to any psychedelic substances such as psilocybin, in
the case where if they hadn’t been exposed to the substance they would not have developed any
form of psychosis (Ziff et al. 8). This is however, managed under psilocybin-assisted therapy as
before being able to receive it, all patients must undergo medical health screening to ensure it
will be an appropriate option for them. Many of the clinical studies on PAT usually begin with a
large pool of participants, which is slowly trickled down to a very small number via medical
health screening. The doses of psilocybin provided by these clinics are also quite moderate, and
typically less than even 1 gram which is the starting dose for recreational users. Years of research
and studies have gone on to show that psilocybin-assisted therapy can bring profound
improvement to depressive symptoms, especially for those who have exhausted all other options
such as medications and therapy. Age, health, and environment are all factors to consider when it
comes to PAT and it should be offered based on a mutual decision between the patient and their
mental healthcare provider. Although psilocybin-assisted therapy is not currently offered as an
official treatment and can only be accessed by participating in clinical trials, this may change
soon. In 2018, the FDA granted psilocybin-assisted therapy “break-through therapy” status
which means they will prioritize reviewing it soon for approval meaning it could soon be widely
offered for treatment (Coleman). For those struggling with depression who haven’t found relief
from any of the current treatment options, or are interested in trying psilocybin-assisted therapy,
this may be good news. Still, as in all cases, it’s important to do your own research to determine
whether this is the right option for you.

  1. Alshaikhli, Hisham, et al. “Effectiveness of Psilocybin on Depression: A Qualitative Study.”
    Electronic Journal of General Medicine, vol. 18, no. 3, Apr. 2021, p. em296,
    https://doi.org/10.29333/ejgm/10862.
  2. Coleman, Theara, and The Week US last updated. “The Legal State of Psychedelic Therapy in
    the US.” The week, 25 June 2023,
    theweek.com/drugs/1024449/the-state-of-psychedelic-therapy-in-the-us. Accessed 26
    Oct. 2023.
  3. Guss, Jeffrey, et al. “The Yale Manual for Psilocybin-Assisted Therapy of Depression (Using
    Acceptance and Commitment Therapy as a Therapeutic Frame).” Yale Manual for
    Psilocybin-Assisted Therapy of Depression , Aug. 2020,
    https://doi.org/10.31234/osf.io/u6v9y. Accessed 4 Nov. 2021.
  4. Kuceyeski, Dr. Amy. “Psychedelic Drugs Flatten the Brain’s Dynamic Landscape.” WCM
    Newsroom, Weill Cornell Medicine, 2022,
    news.weill.cornell.edu/news/2022/10/psychedelic-drugs-flatten-the-brain%E2%80%99s
    dynamic-landscape
    .
  5. Lowe, Henry, et al. “The Therapeutic Potential of Psilocybin.” Molecules, vol. 26, no. 10, Jan. 2021, p. 2948, https://doi.org/10.3390/molecules26102948.
  6. Malone, Tara C., et al. “Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy.” Frontiers in Pharmacology, vol. 9, 2018, p. 335252, https://doi.org/10.3389/fphar.2018.00256. Accessed 26 Oct. 2023.
  7. Nichols, David E. “Psilocybin: From Ancient Magic to Modern Medicine.” The Journal of Antibiotics, vol. 73, no. 10, May 2020, pp. 679–86, https://doi.org/10.1038/s41429-020-0311-8.
  8. Neuroscientifically Challenged. “2-Minute Neuroscience: Psilocybin.” YouTube, YouTube Video, 5 May 2020, www.youtube.com/watch?v=XBEas8MGzd0.
  9. Rotz, Robin, et al. “Single-Dose Psilocybin-Assisted Therapy in Major Depressive Disorder: A Placebo-Controlled, Double-Blind, Randomised Clinical Trial.” EClinicalMedicine, vol. 56, Feb. 2023, p. 101809, https://doi.org/10.1016/j.eclinm.2022.101809.
  10. Schuitmaker, Nicole. “Psilocybin-Assisted Therapy: A Scoping Review of Participants’ and Facilitators’ Experiences in Qualitative Studies.” Research, Society and Development, vol. 12, no. 9, Sept. 2023, p. e12312943308–e12312943308, https://doi.org/10.33448/rsd-v12i9.43308. Accessed 26 Oct. 2023.
  11. Witters, Dan. “U.S. Depression Rates Reach New Highs.” Gallup.com, 17 May 2023, news.gallup.com/poll/505745/depression-rates-reach-new-highs.aspx#:~:text=In%202023%2C%2029.0%25%20of%20Americans. Accessed 19 Aug. 2023.
  12. Ziff, Shawn, et al. “Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review.” Cureus, vol. 14, no. 2, Feb. 2022, https://doi.org/10.7759/cureus.21944.
  13. “Psychedelic Treatment with Psilocybin Relieves Major Depression, Study Shows.” Www.hopkinsmedicine.org, 4 Nov. 2020, www.hopkinsmedicine.org/news/newsroom/news-releases/2020/11/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows#:~:text=In%20a%20small%20study%20of. Accessed 26 Oct. 2023.
  14. “5 Ways Depression Can Physically Affect the Brain.” Healthline, 24 Oct. 2018, www.healthline.com/health/depression-physical-effects-on-the-brain#reversing-the-effects. Accessed 26 Oct. 2023.